These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38617470)

  • 1. Prognostic impact of tumor marker kinetics and normalization during neoadjuvant chemotherapy for pancreatic cancer.
    Hayashi H; Liu Z; Sun Y; Ogawa D; Baba H
    Hepatobiliary Surg Nutr; 2024 Apr; 13(2):317-320. PubMed ID: 38617470
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Okada K; Takahashi S; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):801-811. PubMed ID: 28314992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer.
    Han X; Zhang WH; Gao HL; Li TJ; Xu HX; Li H; Li PC; Wang X; Yu XJ; Wang WQ; Liu L
    J Clin Lab Anal; 2022 Jul; 36(7):e24517. PubMed ID: 35622458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma.
    Servin-Rojas M; Fong ZV; Fernandez-Del Castillo C; Ferrone CR; Lee H; Lopez-Verdugo F; Qiao G; Rocha-Castellanos DM; Lillemoe KD; Qadan M
    Surgery; 2024 Feb; 175(2):471-476. PubMed ID: 37949693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.
    Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjöhle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellström M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
    ESMO Open; 2021 Apr; 6(2):100076. PubMed ID: 33714010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
    Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum tumor marker normalization in the perioperative period for patients with advanced gastric cancer.
    Hu C; Zhang Y; Xu J; Chen W; Yu P; Wang Y; Bao Z; Zhang R; Xu Z; Cheng X
    Ann Transl Med; 2022 Feb; 10(3):153. PubMed ID: 35284544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.
    Le T; Faught W; Hopkins L; Fung-Kee-Fung M
    J Obstet Gynaecol Can; 2008 Aug; 30(8):665-670. PubMed ID: 18786288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection.
    Fong ZV; Severs G; Moir J; White S; Qadan M; Tingle S
    HPB (Oxford); 2024 Mar; 26(3):418-425. PubMed ID: 38135550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
    Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Sueda T
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):37-47. PubMed ID: 27878355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.
    Maeda S; Mederos MA; Chawla A; Moore AM; Shoucair S; Yin L; Burkhart RA; Cameron JL; Park JY; Girgis MD; Wainberg ZA; Hines OJ; Fernandez-Del Castillo C; Qadan M; Lillemoe KD; Ferrone CR; He J; Wolfgang CL; Burns WR; Yu J; Donahue TR
    Surgery; 2022 May; 171(5):1379-1387. PubMed ID: 34774289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
    Ghabi EM; Shoucair S; Ding D; Javed AA; Thompson ED; Zheng L; Cameron JL; Wolfgang CL; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; He J
    J Gastrointest Surg; 2023 Apr; 27(4):691-700. PubMed ID: 36280632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery.
    Ando Y; Dbouk M; Blackford AL; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Sokoll L; Eshleman JR; Burkhart R; He J; Goggins M
    Ann Surg Oncol; 2024 May; 31(5):2902-2912. PubMed ID: 38319515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.
    Thalji SZ; Aldakkak M; Christians KK; Clarke CN; George B; Kamgar M; Erickson BA; Hall WA; Chisholm P; Kulkarni N; Doucette S; Evans DB; Tsai S
    J Surg Oncol; 2023 Jul; 128(1):41-50. PubMed ID: 36960919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.